Abstract P6-09-52: Prognostic factors in breast cancer (BC) associated with the development of brain metastases (BM): A retrospective study of 726 pts

2017 ◽  
Author(s):  
O Santa Cruz ◽  
P Tsoutsou ◽  
S Anchisi ◽  
K Khanfir ◽  
L Negretti ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Prognostic Factors ◽  
Retrospective Study ◽  
Brain Metastases

scholarly journals Malignant melanoma brain metastases: Treatment results and prognostic factors - a single-center retrospective study

2015 ◽  
Vol 46 (6) ◽  
pp. 2439-2448 ◽  
Author(s):  
CHRISTIAN OSTHEIMER ◽  
CAROLINE BORMANN ◽  
ECKHARD FIEDLER ◽  
WOLFGANG MARSCH ◽  
DIRK VORDERMARK
Keyword(s):  
Prognostic Factors ◽  
Retrospective Study ◽  
Malignant Melanoma ◽  
Brain Metastases ◽  
Single Center ◽  
Treatment Results ◽  
Melanoma Brain Metastases

scholarly journals Survival outcomes of breast cancer patients with brain metastases: A multicenter retrospective study in Korea (KROG 16–12)

The Breast ◽  
2020 ◽  
Vol 49 ◽  
pp. 41-47 ◽  
Author(s):  
Jae Sik Kim ◽  
Kyubo Kim ◽  
Wonguen Jung ◽  
Kyung Hwan Shin ◽  
Seock-Ah Im ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Retrospective Study ◽  
Brain Metastases ◽  
Cancer Patients ◽  
Survival Outcomes ◽  
Breast Cancer Patients

scholarly journals PO101 PROGNOSTIC FACTORS AFTER GAMMA KNIFE RADIOSURGERY IN BREAST CANCER PATIENTS WITH BRAIN METASTASES

The Breast ◽  
2015 ◽  
Vol 24 ◽  
pp. S56
Author(s):  
Shoko Hayama ◽  
Osamu Nagano ◽  
Naohito Yamamoto ◽  
Takeshi Nagashima ◽  
Rikiya Nakamura ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Prognostic Factors ◽  
Brain Metastases ◽  
Cancer Patients ◽  
Gamma Knife ◽  
Gamma Knife Radiosurgery ◽  
Breast Cancer Patients

Prognostic factors and survival according to tumour subtype in women presenting with breast cancer brain metastases at initial diagnosis

2017 ◽  
Vol 74 ◽  
pp. 17-25 ◽  
Author(s):  
José Pablo Leone ◽  
Julieta Leone ◽  
Ariel Osvaldo Zwenger ◽  
Julián Iturbe ◽  
Bernardo Amadeo Leone ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Prognostic Factors ◽  
Brain Metastases ◽  
Initial Diagnosis ◽  
Breast Cancer Brain Metastases

scholarly journals RADI-17. Outcomes for patients with triple negative breast cancer treated with upfront stereotactic radiosurgery for brain metastases

2021 ◽  
Vol 3 (Supplement_3) ◽  
pp. iii21-iii21
Author(s):  
Ran An ◽  
Yan Wang ◽  
Fuchenchu Wang ◽  
Akshara Singareeka Raghavendra ◽  
Chao Gao ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Prognostic Factors ◽  
Brain Metastases ◽  
Stereotactic Radiosurgery ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Univariate Analysis ◽  
Karnofsky Performance Score ◽  
Risk Of Death ◽  
Metastatic Sites

Abstract Background Triple-negative breast cancer (TNBC) is an aggressive subtype with high propensity of developing brain metastases (BM). Clinical outcomes and prognostic factors after stereotactic radiosurgery (SRS) for BM were not well defined. Methods We identified 57 consecutive TNBC patients (pts) treated with single fraction SRS for BM during 05/2008–04/2018. Overall survival (OS) from BM diagnosis and freedom from BM progression (FFBMP) after initial SRS were evaluated. BM progression was defined as local and/or distant brain failure (LBF, DBF) after SRS. Kaplan-Meier analyses and Cox proportional hazard regression were used to estimate survival outcomes and identify prognostic factors. Results The median time to BM development from TNBC diagnosis was 23.7 months (mo) (range 0.7‒271.1). Median OS was 13.1 mo (95%CI 8.0‒19.5). On univariate analysis, Karnofsky performance score (KPS) >70 (p=0.03), number of BMs <3 (p=0.016), and BM among the first metastatic sites (p=0.04) were associated with longer OS. On multivariate analysis, KPS ≤70 was associated with higher risk of death (HR 3.0, p=0.03). Of 46 pts with adequate imaging follow-up, 29 (63%) had intracranial progression with a median FFBMP of 7.4 mo (95% CI 5.7–12.7). At 12 mo the estimated cumulative DBF rate was 61.1% (95%CI 40.8%–74.4%) and LBF rate was 17.8% (95%CI 2%–31.1%). Number of BMs (≥3 vs <3) was not associated with FFBMP (p=0.7). Of the 29 pts with BM progression, additional radiation therapy (RT) (vs. no RT) was associated with improved survival (21.7 vs. 7.0 mo, p<0.0001). Conclusions TNBC pts with BM treated with SRS had an OS of 13.1 mo and FFBMP of 7.4 mo. Good KPS was an independent prognostic factor for OS. Further studies with more pts or conducted prospectively are needed to better understand and to improve treatment outcomes in this pt population.

Multidisciplinary management of brain metastases from non-small cell lung cancer: A retrospective study of 251 patients

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. e19030-e19030
Author(s):  
M. Shenglin ◽  
X. Yaping ◽  
Y. Xinmin ◽  
Y. Yang
Keyword(s):  
Lung Cancer ◽  
Weight Loss ◽  
Prognostic Factors ◽  
Retrospective Study ◽  
Brain Metastasis ◽  
Brain Metastases ◽  
Blood Serum ◽  
Small Cell ◽  
Multidisciplinary Management ◽  
Small Cell Lung

e19030 Background: The detection of brain metastasis(BM) is becoming increasingly common in patients with non-small cell lung cancer (NSCLC). The aim of this study was to evaluate clinical course, prognostic significance, and treatment efficacy in patients with brain metastasis. Methods: The records of all patients with BM from December 2003 to January 2007 were reviewed, and a retrospective study of 251 patients with cytologically and histologically diagnosed NSCLC and brain metastasis detected by cranial computed tomography or magnetic resonance imaging was performed. Variables analyzed included the recursive partitioning analysis (RPA) grouping, weight loss, LDH in blood serum, sex, age, time of brain metastasis (synchronous vs. metachronous), number of brain metastases, maximum diameter of largest brain lesion, Karnofsky performance status, histologic type (adenocarcinoma vs. other types of NSCLC), TNM stage (without consideration of brain involvement), and the treatment modality used for both the primary NSCLC tumor and brain metastasis. Results: The overall 1-, 2- and 3-year survival rates were 34.1%, 13.7% and 8.7% with a median survival time of 9.0 months (95% CI 8.04–9.97 months). On multivariate analysis, RPA grouping, weight loss, LDH in blood serum and treatment were independent prognostic factors. The median overall survival (OS) time of chemotherapy alone, whole brain radiotherapy (WBRT) alone, surgery alone, WBRT with chemotherapy, surgery with chemoradiation, WBRT with Gefitinib and others management was 6.0, 9.0, 12.0, 9.0, 22.0, 13.0 and 4.0 months, respectively, which were significantly different (X2=43.104, P=0.000). The stratify analysis indicated the median OS of patients received concurrent WBRT/chemotherapy (13.0 months) was longer than it of patients received sequential WBRT/chemotherapy (9.0 months) (X2=3.89,P=0.049). Conclusions: The main prognostic factors of BM from NSCLC of pretreatment are RAP grouping, weight loss and LDH in blood serum. The effect of combined treatment of surgery with chemoradiation is favorable and the choice of the patient is important. The survival are prolonged by active multidisciplinary management of brain metastases. [Table: see text]

Sign in / Sign up

Export Citation Format

Share Document